At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 86 enrolled
Drug / intervention
Brinzolamide 1% ophthalmic solution (Azopt) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Brinzolamide Ophthalmic Suspension, 1% (Azopt) TID vs. Placebo TID Added to Latanoprost Ophthalmic Solution, 0.005% (Xalatan) in Patients With Elevated IOP on a Prostaglandin
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, and 1 other intervention for Glaucoma. Completed, enrolled 86 participants across 1 site.
Detailed Summary
The purpose of this study was to assess the efficacy of adding Azopt dosed three times a day to Xalatan as compared to that of adding placebo to Xalatan in patients with elevated intraocular pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedSep 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.8 years ago
Interventions
Brinzolamide 1% ophthalmic solution (Azopt)drug
One drop three times a day in both eyes for 3 months
Placebo eye dropsdrug
One drop three times a day in both eyes for 3 months
Latanoprost 0.005% ophthalmic solution (Xalatan)drug
One drop once a day in both eyes for 3 months